PMC:7402624 / 38718-38833 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T355","span":{"begin":44,"end":46},"obj":"Body_part"},{"id":"T356","span":{"begin":84,"end":89},"obj":"Body_part"}],"attributes":[{"id":"A355","pred":"fma_id","subj":"T355","obj":"http://purl.org/sig/ont/fma/fma84371"},{"id":"A356","pred":"fma_id","subj":"T356","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Approximately 42% of patients had sustained PB responses, at high levels (\u003e10% of B cells) in many cases (Fig. 5F)."}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"1373","span":{"begin":21,"end":29},"obj":"Species"},{"id":"1377","span":{"begin":44,"end":46},"obj":"Chemical"}],"attributes":[{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Approximately 42% of patients had sustained PB responses, at high levels (\u003e10% of B cells) in many cases (Fig. 5F)."}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T305","span":{"begin":44,"end":46},"obj":"Disease"}],"attributes":[{"id":"A305","pred":"mondo_id","subj":"T305","obj":"http://purl.obolibrary.org/obo/MONDO_0019035"}],"text":"Approximately 42% of patients had sustained PB responses, at high levels (\u003e10% of B cells) in many cases (Fig. 5F)."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T653","span":{"begin":82,"end":89},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"Approximately 42% of patients had sustained PB responses, at high levels (\u003e10% of B cells) in many cases (Fig. 5F)."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T270","span":{"begin":44,"end":46},"obj":"Chemical"}],"attributes":[{"id":"A270","pred":"chebi_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/CHEBI_53319"},{"id":"A271","pred":"chebi_id","subj":"T270","obj":"http://purl.obolibrary.org/obo/CHEBI_60686"}],"text":"Approximately 42% of patients had sustained PB responses, at high levels (\u003e10% of B cells) in many cases (Fig. 5F)."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T223","span":{"begin":0,"end":115},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Approximately 42% of patients had sustained PB responses, at high levels (\u003e10% of B cells) in many cases (Fig. 5F)."}